Clinical Trial Update: Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing hFSH-HP (Fostipur) versus hMG-HP (Meriofert) in IVF/ICSI cycles for patients with Polycystic Ovary Syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• hFSH-HP (Fostipur) (fostipur? (assuming hFSH-HP is recombinant human follicle-stimulating hormone))
• hMG-HP (Meriofert) (human menopausal gonadotropin -HP)

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Polycystic Ovary Syndrome | Phase 4 | Status: TERMINATED